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96.5% (N193), with N180 indicating continuous use. N141 patients (71%) had a
hospitalization with average 3.5 hospitalizations per patient (median2); an aver-
age patient spent 48 days in hospital during the study period. On average, for those
with a procedure, 1.8 (SD1.4) surgical (N55) or 7.9 (SD5.8) diagnostic (N200)
procedures were recorded. No differences were observed between G551D and
DF508 genotypes in terms of severity of disease as gauged by health care use.
CONCLUSIONS: This study, linking both clinical and resources use information
indicates that high frequency and intensity of health care resource use contributes
substantially to the overall burden of CF in UK. G551D and 	F508 genotypes appear
to have similar patterns of resource utilization.
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OBJECTIVES: Long-acting 2-agonists (LABAs), such as formoterol fumarate (for-
moterol) and salmeterol xinafoate (salmeterol), play key roles in the management
of asthma and chronic obstructive pulmonary disease. This analysis evaluated new
prescriptions of inhaled LABAs for respiratory disease in five European countries
during 2011. METHODS: Data on new prescriptions for LABAs, as either a single
drug or a fixed-dose combination (FDC), were collected from anonymized patient
records obtained via primary care physician practice management software (Cege-
dim Strategic Data, Surrey, UK) from January until December 2011 in five European
countries (France, Germany, Italy, Spain and UK). New prescriptions were defined
as those issued to patients who had not received a product from the selected
market in the previous 12 months; patients who were prescribed a LABA or FDC
therapy as a replacement for an existing therapy; and patients for whom a LABA
was added to their continued, original therapy. RESULTS:Overall, there were more
than 7.44 million new prescriptions for LABAs during 2011, either as monotherapy
(1.38. million; 18.5%) or as FDCs (6.07 million; 81.5%). Formoterol accounted for
55.2% (4.11 million) of all new LABA prescriptions, compared with 39.7% (2.96 mil-
lion) for salmeterol and 5.1% (0.38 million) for indacaterol. Formoterol comprised
53.7% of LABA monotherapy prescriptions compared with 18.8% for salmeterol and
27.5% for indacaterol. For FDCs, formoterol accounted for 55.5% of new prescrip-
tions (budesonide/formoterol, 32.8%; beclometasone/formoterol, 22.7%) compared
with 44.5% for salmeterol/fluticasone.CONCLUSIONS: Formoterol is the most com-
monly prescribed inhaled LABA for patients with respiratory disease, who are
newly prescribed LABA therapy, as either a single drug or combination therapy, in
the five largest European countries. These data may reflect, at least in part, physi-
cian preference for formoterol-containing regimens based on their well-estab-
lished efficacy profile.
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OBJECTIVES: To evaluate the association between persistent use of statins and the
risk of incident psoriasis among primary prevention patients in community
settings.METHODS:A cohort of 205,820 adults aged21 years, with no indication
of psoriasis or psoriatic arthritis, who began statin therapy between 1998 and 2009
in Maccabi Healthcare Services, a large health maintenance organization in Israel,
was followed retrospectively for psoriasis. Persistence with statins was measured
by the proportion of days covered (PDC) with dispensed prescriptions of statins
during follow-up period. Psoriasis was counted if diagnosed by a dermatologist or
at release from hospitalization. Sex-stratified Cox proportional hazards regression
was used for analysis of risk of psoriasis by PDC level, adjusting for baseline demo-
graphic and clinical characteristics, initial statin efficacy and baseline use of
beta-blockers. RESULTS: A total of 5160 cases of incident psoriasis were identified
during the follow-up period (1.3 million person-years) with incidence density rate
of 4.40/1,000PY (95% CI: 4.29-4.52). Multivariate analysis revealed a U-shaped asso-
ciation between persistence with statins and onset of psoriasis. In comparison with
non-persistent users (20% PDC), in women, HRs declined with increasing PDC to
0.74 (95% CI: 0.65-0.85) in the 40-60% PDC group and then increased up to 0.88
(0.79-0.98) in the most persistent group (80% PDC). In men, HRs declined to 0.84
(0.74-0.95) and then increased up to 1.00 (0.90-1.11) in respective PDC groups. Lim-
iting analyses to patients with more than 5 years of follow-up yielded similar
results. Beginning treatment with high efficacy statins was associated with an
11-18% reduced risk of psoriasis. CONCLUSIONS: Our large community-based study
indicates a U-shaped association between statins use and the risk of psoriasis.
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This research was carried out during a review of the manufacturer’s submission
(MS) to the NICE Single Technology Appraisal programme for the humanised re-
combinant monoclonal antibody fragment, ranibizumab. OBJECTIVES: Although
novel agents for the treatment of MO secondary to branch RVO (BRVO) or central
RVO (CRVO) are available, there is limited evidence on their clinical effectiveness
compared with existing treatments, and with each other. This research compared
the clinical effectiveness of ranibizumab versus standard care, dexamethasone
intravitreal implant (dexamethasone), and bevacizumab in patients with MO sec-
ondary to CRVO or to BRVO. METHODS: Randomised controlled trials (RCTs) for
inclusion were identified using the MS for ranibizumab. RCTs were assessed for
comparability based on treatment regimen, patient population, and disease sever-
ity. Adjusted indirect comparisons and a linear network analysis (3 RCTs) were
performed. Summary statistics used were relative risk of achieving an improve-
ment of 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters and
mean difference (MD) in ETDRS letters from baseline. RESULTS: Indirect compari-
sons of ranibizumab versus dexamethasone indicated a relative risk of achieving
an improvement of 15 letters or more of 0.53 (95% CI: 0.26 to 1.07) in MO secondary
to CRVO at 6 months and 0.56 (95% CI: 0.33 to 0.96) in MO secondary to BRVO at 3
months. In MO secondary to BRVO, a linear network analysis indicated an MD of
–2.9 ETDRS letters (95% Credible interval [CrI]: –10.0 to4.3) between bevacizumab
and ranibizumab, and an MD of –8.0 ETDRS letters (95% CrI: –17.0 to1.2) between
grid laser photocoagulation (standard care) and ranibizumab. The direction of ef-
fect favoured ranibizumab in all analyses. CONCLUSIONS: The available evidence
for analysis is insufficient to draw any firm conclusions on the comparative effects
of active treatments for MO secondary to RVO. Additional RCTs are required.
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OBJECTIVES: To investigate the effect of Epidermal Growth Factor (EGF) plus silver
sulfadiazine (SSD) cream for treatment of burn wound. METHODS: The 34 patients
who have partial thickness burn wounds and admitted at Burn Unit, Siriraj hospital
during December 2011 to April 2012 were randomly divided into 2 groups receiving
the topical treatment either 6% EGF plus 1% SSD cream group (study group) or 1%
silver zinc sulfadiazine cream (control group). The study end point was the time of
completely wound closure. Area of wound measurement and wound dressing was
done every day. Percentage of epithelialization, pain and itching score, pain and
itch medication used and chemistry laboratory results were evaluated every week
until completely wound closure by epithelialization. RESULTS: The demographic
data of both groups was similar with regards to sex, age, weight, social history, vital
sign and wound characteristics. From this study, we found that the study group
had significantly shorter healing time than of the control group. The study group
also had higher percentage of epithelialization at every time points (p0.05). How-
ever, there was no significant difference in percentage of wound contraction be-
tween both groups (p0.05). Pain score and doses of pain-relieved medication used
(paracetamol and morphine) in study group was significantly lower than in the
control group. There was no difference in itching evaluation and itch-relieved med-
ication used and blood chemistry parameters (p0.05). The cost of treatment was
similar in both groups even length of stay in study group was less compared to
control group. CONCLUSIONS: Topical EGF plus silver sulfadiazine enhances
wound healing in partial thickness burn wounds by reduced time of wound closure
without any serious side effects. EGF application may be a new option for burn
wound care in the future.
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OBJECTIVES: Acne is influenced by lifestyle1. Smoking, weight and diet have all
been identified as playing a role. Polls are a quick way to explore a population. The
aim of our study was to investigate factors associated with acne in a representative
sample of the French population reporting acne. METHODS: A total of 10,084 sub-
jects constituting a representative sample of French people aged 15 to 69years were
interviewed by the CSA Health Institute according to the quota method (sex-age-
socio-professional category and location). The questionnaire explored the BMI,
lifestyle, addictions (smoking-alcohol-cannabis), diet, sexuality, stress and physi-
cal activity. The subjects reporting mild, moderate or severe acne were also
compared. RESULTS: A total of 2073 subjects were identified. 843 boys (477cases-
and-366controls) and 1,230 girls (857cases-and-373controls). Among these cases,
46 reported severe-acne, 417 moderate-acne and 871 mild-acne. Overall, the cases
included significantly fewer smokers, more virgin subjects, a higher reported-
stress rate, and a lower BMI. Consumption of alcohol, cannabis and soda, the fre-
quency of fast-food consumption, and the level of physical activity did not differ
between the cases and controls. The severity of acne was not associated with BMI,
physical activity, oral contraception (for girls), sexuality, alcohol consumption or
the feeling of being stressed. However, there was a significantly higher number of
smoking subjects in the severe group compared to the subjects in the moderate and
mild groups (33.3%-18.71%-and-18.37%-respectively-were-smokers). The same
correlation was observed for cannabis, fast-food , soda , daily chocolate/confec-
tionery and dairy product consumption. CONCLUSIONS: There is a link between
lifestyle, acne and its severity. Factors such as smoking and a high-fat or high-
sugar diet seem to be associated with more severe acne. Our results are obtained
from a self-reported population. Nevertheless, and the analysis of our survey sup-
plement the results obtained from a case-control study. We confirm that there is a
link between lifestyle and acne, in particular food.
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